Outseer Protects $100 Billion in Payment Transactions Year-to-Date via 3-D Secure
14.9.2021 16:00:00 EEST | Business Wire | Press release
Outseer, the leader in payment authentication and monitoring solutions, has published its third quarter Fraud & Payments Report, confirming that a massive $100 billion in transactions in 2021 alone have been protected by Outseer’s 3-D secure payments authentication technology. The report also reveals continued explosive growth of worldwide 3-D Secure transactions due to skyrocketing adoption of online shopping and new PSD2 mandates. The Q3 report installment features insights from April through June of 2021 as captured through the Outseer Global Data Network, and collected while authenticating consumer transactions and investigating threats on behalf of Outseer customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005639/en/
(Graphic: Business Wire)
According to the report, 3-D Secure transactions, a global standard supported by EMVCo to authenticate digital payment transactions, have grown by an impressive 79% over the past 18 months, with Q2 year-over-year growth of 44%.
For the latest standard using EMV®3-D Secure 2.x technology specifically, the report shows a continued, steady increase across all geographies. Europe recorded the most significant jump, where 2.x transactions comprised a 46% share of all 3-D Secure transactions examined in Q2, 2021, growing nearly seven times from the 7% share reported in Q3 2020. The Americas witnessed nearly four times growth, with 2.x transaction volume jumping from a 10% share in Q3, 2020 to a 37% share in Q2, 2021.
This global share increase in 2.x transactions can be attributed to a pandemic-fueled spike in card-not-present (CNP) transactions in addition to looming Payment Services Directive (PSD2) enforcement dates. Moreover, the 2.x authentication standard from EMVCo supports consumer-friendly experiences in native mobile app environments tailed to the merchant. As the 3-D Secure standard directly supports PSD2 and Strong Customer Authentication (SCA) regulations, adoption of the 2.x version to authenticate payment transactions will increase beyond March of 2022 when PSD2 regulations go into effect across all of Europe.
“As the pandemic fuels an unprecedented spike in digital shopping globally, we’re excited to see card issuers and merchants embrace the gold standard of payment authentication technology,” said Armen Najarian, CMO and Chief Identity Officer at Outseer. “The latest 3-D Secure standard delivers the shopping experiences consumer demand, with the positive economics and growth that card issuers and merchants require. We expect the global payments ecosystem to deepen its use of 3-D Secure to authenticate digital transactions.”
Other notable insights from the Q3 Outseer Fraud & Payments Report include:
- Over 49,000 attacks detected by the Outseer Anti-Fraud Command Center in Q2 2021 alone
- Brand Abuse attacks continue to be the most dominant attack vector for the third consecutive quarter, comprising 49% of all attack types
- 70% of fraudulent transactions in digital banking originated through the mobile channel, with the biggest rise seen in mobile app fraud
- The presence of Rogue Mobile Apps increased 66% from last quarter and 140% year-over-year. Fraudsters are creating fake banking apps and uploading them to various app stores to infect consumers’ devices with malware and harvest user credentials for account takeover activities
- Outseer recovered over 4.5 million unique compromised cards and card previews from online card stores and fraud communication channels in Q2 2021
Download the Q3, 2021 Outseer Fraud & Payments Report here: https://www.outseer.com/fraud-report-q3-2021/
About Outseer
Outseer, an RSA Company, empowers the digital economy to grow by authenticating billions of transactions annually. Our payment and account monitoring solutions increase revenue and reduce customer friction for card issuing banks, payment processors, and merchants worldwide. Leveraging 20 billion annual transactions from 6,000 global institutions contributing to the Outseer Data Network, our identity-based science delivers the highest fraud detection rates and lowest customer intervention in the industry. See what others can’t at outseer.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005639/en/
Contact information
David Pedersen
David.Pedersen@outseer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
